LMAT Q2 Deep Dive: International Growth and Supply Constraints Shape Results

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 million. Next quarter’s revenue guidance of $67.3 million underwhelmed, coming in 3% below analysts’ estimates. Its GAAP profit of $0.70 per share was 13.8% below analysts’ consensus estimates.

Is now the time to buy LMAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and Asia. However, the quarter fell short of Wall Street’s revenue and profit expectations, which contributed to a negative market reaction. Management attributed the underperformance to a combination of adverse currency impacts, ongoing Middle East export delays, and supply constraints in cardiac allografts. CEO George LeMaitre highlighted that, despite these headwinds, the company saw record sales in key segments and continued to invest in international expansion.

Looking ahead, LeMaitre’s updated guidance reflects ongoing challenges from the same three factors: foreign exchange volatility, Middle East export disruptions, and tightening supply of cardiac allografts. Management is cautiously optimistic about mitigating these issues through infrastructure investments and a growing international sales force. President Dave Roberts emphasized that the company is concentrating near-term efforts on improving cardiac tissue supply in the U.S., while also pursuing regulatory approvals to expand access abroad. The company expects margin improvements from its relocalization strategy and continued high demand for Artegraft in Europe.

Key Insights from Management’s Remarks

Management identified three main reasons for missing expectations: a stronger U.S. dollar, export delays due to the Middle East conflict, and supply limitations in cardiac allografts. At the same time, international expansion and product diversification drove solid underlying growth.

• Artegraft momentum: Artegraft, now LeMaitre’s largest product, grew 34% and accounted for 21% of sales, benefiting from both increased demand and geographic approvals. Management is investing in further international approvals, longer product sizes for European leg bypass procedures (with regulatory filings for longer packaging expected in Q4 2026 and potential sales of these longer grafts not anticipated until the second half of 2027), and a larger sales force to sustain momentum.
• Relocalization strategy: The company’s initiative to localize warehouses and customer service across Europe reduced shipping costs and drove significant margin expansion in the region. CEO George LeMaitre described a “huge shipping savings” and “explosion of gross margin” as a result, particularly in markets like Spain and France.
• Product and market diversification: Record sales in grafts, shunts, and patches, as well as strong double-digit growth in EMEA (Europe, Middle East, Africa) and APAC (Asia-Pacific), offset weaker catheter sales caused by prior-year recall-driven overstocking. Management believes these trends highlight the resilience of the portfolio outside isolated challenges.
• Supply constraints in cardiac allografts: Ongoing difficulties in securing adequate tissue supply have slowed growth in this segment. The company is moving tissue processing to its Burlington, Massachusetts headquarters and has utilized operational tools like the Donor IQ program in the background, though management notes that supply constraints persist and Donor IQ's impact is not the principal bottleneck solution at this time.
• Sales force expansion: LeMaitre continues to increase its global commercial presence, aiming for 170-180 sales representatives by year's end (up from 163 in Q2, with nine already signed to start in Q3 and thirteen more positions open). This increase is projected for year-end, not yet achieved, and is expected to support growth in both legacy and newly approved international markets.

Drivers of Future Performance

LeMaitre’s outlook for the coming quarters is shaped by efforts to combat supply challenges, manage currency impacts, and support expansion through infrastructure investment and sales force growth.

• International expansion as a growth driver: The company is prioritizing Artegraft approvals and launches in new countries, including recent wins in Vietnam, Morocco, and Turkey, and is preparing for larger markets like Korea, Brazil, and India by 2027. Canada’s launch is imminent, and expanded warehouse infrastructure—including new or larger facilities in Madrid, Paris, Toronto, Warsaw, and Hereford/London, some of which are not yet operational but planned for late 2026/2027—is expected to improve delivery efficiency and customer relationships.
• Managing supply constraints and R&D pipeline: Addressing cardiac allograft supply remains a central focus, with operational changes aimed at relocating tissue processing and the recent removal of certain procurement constraints. However, management emphasized that supply remains an ongoing issue despite these steps. New product development, such as the Quick Stick project, faces longer timelines due to likely FDA clinical trial requirements, which could delay U.S. market entry for years.
• Margin improvement through relocalization: The relocalization project, particularly in Europe, is expected to drive gross and operating margin gains, despite increased investments in sales and infrastructure. Management believes these initiatives will position the company for higher profitability as international sales mix rises.

Catalysts in Upcoming Quarters

Looking forward, key upcoming catalysts include (1) the success of Artegraft expansion in new and existing international markets, (2) progress on resolving cardiac allograft supply constraints via operational changes and partnerships, and (3) the impact of warehouse relocalization on margin improvement and customer satisfaction. Updates on regulatory approvals and new product development timelines will also be important for tracking execution.

LeMaitre currently trades at $88.02, down from $105.78 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.